Related Experiment Video
Updated: Mar 6, 2026
Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines
Published on: June 23, 2019
Synthesis and Evaluation of New Pyrazoline Derivatives as Potential Anticancer Agents in HepG-2 Cell Line
Weijie Xu1, Ying Pan2, Hong Wang3
1Department of Chemistry, Shantou University Medical College, Shantou 515041, Guangdong, China. 13536920534@163.com.
Abstract:
Cancer is a major public health concern worldwide. Adverse effects of cancer treatments still compromise patients' quality of life. To identify new potential anticancer agents, a series of novel pyrazoline derivatives were synthesized and evaluated for cytotoxic effects on HepG-2 (human liver hepatocellular carcinoma cell line) and primary hepatocytes. Compound structures were confirmed by ¹H-NMR, mass spectrometry, and infrared imaging. An in vitro assay demonstrated that several compounds exerted cytotoxicity in the micromolar range. Benzo[b]thiophen-2-yl-[5-(4-hydroxy-3,5-dimethoxy-phenyl)-3-(2-hydroxy-phenyl)-4,5-dihydo-pyrazol-1-yl]-methanone (b17) was the most effective anticancer agent against HepG-2 cells owing to its notable inhibitory effect on HepG-2 with an IC50 value of 3.57 µM when compared with cisplatin (IC50 = 8.45 µM) and low cytotoxicity against primary hepatocytes. Cell cycle analysis and apoptosis/necrosis evaluation using this compound revealed that b17 notably arrested HepG-2 cells in the G₂/M phase and induced HepG-2 cells apoptosis. Our findings indicate that compound b17 may be a promising anticancer drug candidate.
Insights
Researchers developed novel pyrazoline derivatives to combat cancer. Compound b17 showed significant anticancer activity against liver cancer cells (HepG-2) with low toxicity to healthy cells, indicating its potential as a new drug candidate.
Area of Science:
- Medicinal Chemistry
- Organic Synthesis
- Cancer Research
Background:
- Cancer remains a significant global health challenge, with current treatments often causing adverse effects that diminish patients' quality of life.
- There is a continuous need for novel therapeutic agents with improved efficacy and reduced toxicity for cancer treatment.
Purpose of the Study:
- To synthesize and evaluate novel pyrazoline derivatives as potential anticancer agents.
- To assess the cytotoxic effects of these compounds on HepG-2 (human liver hepatocellular carcinoma) cells and primary hepatocytes.
- To identify specific compounds with potent anticancer activity and favorable safety profiles.
Main Methods:
- Synthesis of novel pyrazoline derivatives.
- Confirmation of compound structures using techniques including ¹H-NMR, mass spectrometry, and infrared imaging.
- In vitro cytotoxic evaluation against HepG-2 cells and primary hepatocytes, including IC50 determination and cell cycle/apoptosis analysis.
Main Results:
- Several synthesized pyrazoline derivatives exhibited cytotoxicity against HepG-2 cells in the micromolar range.
- Compound b17 demonstrated superior efficacy against HepG-2 cells (IC50 = 3.57 µM) compared to cisplatin (IC50 = 8.45 µM), with significantly lower cytotoxicity towards primary hepatocytes.
- Compound b17 induced G₂/M cell cycle arrest and apoptosis in HepG-2 cells.
Conclusions:
- Compound b17, a novel pyrazoline derivative, exhibits potent and selective anticancer activity against human liver hepatocellular carcinoma cells.
- The mechanism of action for b17 involves inducing cell cycle arrest and apoptosis.
- Compound b17 represents a promising candidate for further development as an anticancer therapeutic agent.
